Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets - PubMed (original) (raw)
. 2003 Dec;144(12):5149-58.
doi: 10.1210/en.2003-0323. Epub 2003 Aug 28.
Affiliations
- PMID: 12960095
- DOI: 10.1210/en.2003-0323
Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets
Loredana Farilla et al. Endocrinology. 2003 Dec.
Abstract
The peptide hormone, glucagon-like peptide 1 (GLP-1), has been shown to increase glucose-dependent insulin secretion, enhance insulin gene transcription, expand islet cell mass, and inhibit beta-cell apoptosis in animal models of diabetes. The aim of the present study was to evaluate whether GLP-1 could improve function and inhibit apoptosis in freshly isolated human islets. Human islets were cultured for 5 d in the presence, or absence, of GLP-1 (10 nm, added every 12 h) and studied for viability and expression of proapoptotic (caspase-3) and antiapoptotic factors (bcl-2) as well as glucose-dependent insulin production. We observed better-preserved three-dimensional islet morphology in the GLP-1-treated islets, compared with controls. Nuclear condensation, a feature of cell apoptosis, was inhibited by GLP-1. The reduction in the number of apoptotic cells in GLP-1-treated islets was particularly evident at d 3 (6.1% apoptotic nuclei in treated cultures vs. 15.5% in controls; P < 0.01) and at d 5 (8.9 vs. 18.9%; P < 0.01). The antiapoptotic effect of GLP-1 was associated with the down-regulation of active caspase-3 (P < 0.001) and the up-regulation of bcl-2 (P < 0.01). The effect of GLP-1 on the intracellular levels of bcl-2 and caspase-3 was observed at the mRNA and protein levels. Intracellular insulin content was markedly enhanced in islets cultured with GLP-1 vs. control (P < 0.001, at d 5), and there was a parallel GLP-1-dependent potentiation of glucose-dependent insulin secretion (P < 0.01 at d 3; P < 0.05 at d 5). Our findings provide evidence that GLP-1 added to freshly isolated human islets preserves morphology and function and inhibits cell apoptosis.
Comment in
- Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis.
Drucker DJ. Drucker DJ. Endocrinology. 2003 Dec;144(12):5145-8. doi: 10.1210/en.2003-1147. Endocrinology. 2003. PMID: 14645210 Review. No abstract available.
Similar articles
- Pancreatic beta-cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugs.
D'Amico E, Hui H, Khoury N, Di Mario U, Perfetti R. D'Amico E, et al. J Mol Endocrinol. 2005 Apr;34(2):377-90. doi: 10.1677/jme.1.01655. J Mol Endocrinol. 2005. PMID: 15821104 - Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.
Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R. Farilla L, et al. Endocrinology. 2002 Nov;143(11):4397-408. doi: 10.1210/en.2002-220405. Endocrinology. 2002. PMID: 12399437 - Functional maturation of fetal porcine beta-cells by glucagon-like peptide 1 and cholecystokinin.
Hardikar AA, Wang XY, Williams LJ, Kwok J, Wong R, Yao M, Tuch BE. Hardikar AA, et al. Endocrinology. 2002 Sep;143(9):3505-14. doi: 10.1210/en.2001-211344. Endocrinology. 2002. PMID: 12193564 - The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
Lam NT, Kieffer TJ. Lam NT, et al. Minerva Endocrinol. 2002 Jun;27(2):79-93. Minerva Endocrinol. 2002. PMID: 11961501 Review. - The role of GLP-1 in the life and death of pancreatic beta cells.
Perfetti R, Hui H. Perfetti R, et al. Horm Metab Res. 2004 Nov-Dec;36(11-12):804-10. doi: 10.1055/s-2004-826167. Horm Metab Res. 2004. PMID: 15655712 Review.
Cited by
- Novel Phenoxyalkanoic Acid Derivatives as Free Fatty Acid Receptor 4 Agonists for Treating Type 2 Diabetes Mellitus.
Li X, Zhang X, Xie X, Dong T, Lv C, Guan R, Zhang W, Ji G, Chen F, Wang S, Wang X. Li X, et al. Int J Mol Sci. 2024 Oct 25;25(21):11476. doi: 10.3390/ijms252111476. Int J Mol Sci. 2024. PMID: 39519029 Free PMC article. - Glucagon-Like Peptide Receptor-1 Agonists Used for Medically-Supervised Weight Loss in Patients With Hip and Knee Osteoarthritis: Critical Considerations for the Arthroplasty Surgeon.
Heckmann ND, Palmer R, Mayfield CK, Gucev G, Lieberman JR, Hong K. Heckmann ND, et al. Arthroplast Today. 2024 Jun 27;27:101327. doi: 10.1016/j.artd.2024.101327. eCollection 2024 Jun. Arthroplast Today. 2024. PMID: 39071832 Free PMC article. - The effects of gut microbiome manipulation on glycemic indices in patients with non-alcoholic fatty liver disease: a comprehensive umbrella review.
Vakilpour A, Amini-Salehi E, Soltani Moghadam A, Keivanlou MH, Letafatkar N, Habibi A, Hashemi M, Eslami N, Zare R, Norouzi N, Delam H, Joukar F, Mansour-Ghanaei F, Hassanipour S, Samethadka Nayak S. Vakilpour A, et al. Nutr Diabetes. 2024 May 10;14(1):25. doi: 10.1038/s41387-024-00281-7. Nutr Diabetes. 2024. PMID: 38729941 Free PMC article. - Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study.
Jiang Y, Bai HS, Liu GX, Wang SY, Yin L, Hou ZT, Zhao CY, Fan GJ. Jiang Y, et al. Front Endocrinol (Lausanne). 2024 Mar 8;15:1347684. doi: 10.3389/fendo.2024.1347684. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38524632 Free PMC article. - Engineered probiotics introduced to improve intestinal microecology for the treatment of chronic diseases: present state and perspectives.
Guo J, Zhou B, Niu Y, Liu L, Yang L. Guo J, et al. J Diabetes Metab Disord. 2023 Sep 5;22(2):1029-1038. doi: 10.1007/s40200-023-01279-1. eCollection 2023 Dec. J Diabetes Metab Disord. 2023. PMID: 37975092 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials